Login | SITEMAP | FAQS

about icvs | People | CELINEGONCALVES

 

Name: Céline Saraiva Gonçalves

Office: I1.02

School Phone: +351 253 604 837

Email: celinegoncalves@med.uminho.pt

 

 

 

Keywords: Neuro-oncology Cell signaling Transcriptomics Drug response

About

Céline S. Gonçalves (CG) graduated in Biochemistry in 2011 (School of Sciences, University of Minho – UM) and completed her master’s degree in Health Sciences in 2013 (School of Medicine, UM). In 2018, she completed her Ph.D. degree in Health Sciences (School of Medicine, UM). Throughout her research career, CG has been mainly interested in the study of the pathophysiology of brain tumors. Of all brain tumors, her studies mainly focused on glioblastoma (GBM) which is the most common and lethal brain tumor in adults (median overall survival of approximately 15 months after the diagnosis). Despite being only palliative, surgery, radiotherapy, and temozolomide-based chemotherapy are still the gold standard treatments. In this context, her research focuses on: (1) the identification of new prognostic and therapeutic molecular targets for precision strategies, based on tumor intrinsic signaling pathways; and (2) the characterization of their functional and molecular mechanisms, which is still of paramount importance to ultimately improve the outcome of GBM patients. To answer these scientific and clinical questions, she profits from data obtained using several GBM models (from in vitro and in vivo models, to patient-derived tumor samples) and large GBM patients’ cohorts (big data analysis).


Fellowships:

2009-2010: Research Student Fellow – Integration into Research Grant (BII) under the project: "Preparation of precursor for enantioselective synthesis of azasugar by Diels-Alder methodology" – Chemistry Research Centre - Sciences School, University of Minho

01/2014-08/2014: Research Student Fellow under the project: "The Transcriptome of the Oncogenic HOXA9 Homeoprotein in Human Glioblastoma: Functional and Clinical Relevance" (PTDC/SAU-GMG/113795/2009) – Life and Health Sciences Research Institute (ICVS) - Health Sciences School, University of Minho

09/2014-09/2018: PhD Student Fellow  – Life and Health Sciences Research Institute (ICVS) - Health Sciences School, University of Minho


Honors and Prizes:

2005: Diploma of Merit assigned by the Rotary Club

2009: Diploma of Merit Monsenhor Elísio Araújo

2013: Best Poster Award at the XXII Porto Cancer Meeting

          Best Poster Award - VI National Meeting of the Portuguese Association of Neuro-Oncology

          Travel Award funded by the FAPESP

2014: PhD scholarship from the Portuguese Science Foundation (FCT)

          Best oral presentation - VII National Meeting of the Portuguese Association of Neuro-Oncology

2016: EACR24 Meeting Bursary Award

2017: Best oral communication - X National Meeting of the Portuguese Association of Neuro-Oncology

          Scholarships for School Merit in 2012/2013

          Best poster award - 1st ICVS Open Day

2018: Best poster award - 3rd ASPIC International Congress

          Best poster award 2nd ICVS Open Day 

2019: Best oral presentation - XI National Meeting of the Portuguese Association of Neuro-Oncology


Chapter of Book:

Céline S. Gonçalves, Tatiana Lourenço, Ana Xavier-Magalhães, Marta Pojo, Bruno M. Costa (2013). Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights. In: Lichtor T, editor. Evolution of the Molecular Biology ofBrain Tumors and the Therapeutic Implications: InTech.

Céline Gonçalves, Ana Xavier Magalhães and Bruno Marques Costa. (2012). Molecular Pathology of Glioma. In: Ana Xavier Magalhães and Bruno Marques Costa. Molecular Determinants of Glioma Risk and Patient Prognosis. U.S.A.: LAP LAMBERT Academic Publishing GmbH & Co. p31-55.

Key Publications:

Pojo M, Gonçalves CS, Xavier-Magalhães A, Fernandes R, Gonçalves T, Rodrigues AJ, Costa S, Pinto L, Reis RM, Rocha M, Costello JF, Sousa N, Costa BM. “A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to chemotherapy”, Oncotarget. 2015; 6(10): 7657-7674.

Vieira de Castro J, Gonçalves CS, Costa S, Linhares P, Vaz R, Nabiço R, Amorim J, Pereira M, Reis RM, Costa BM. “Impact of TGF-ß1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis”, Tumour Biol. 2015; 36(8): 6525-6532.

Gonçalves, Céline S., Ana Xavier-Magalhães, Marta Pojo, Ana Isabel Oliveira, Sara Correia, Rui M. Reis, Nuno Sousa, Miguel Rocha, and Bruno M. Costa. “Transcriptional Profiling of Hoxa9-Regulated Genes in Human Glioblastoma Cell Models”, Genomics Data. 2015; 5(0): 54-58.

Xavier-Magalhaes, A. I. Oliveira, J. V. de Castro, M. Pojo, C. S. Goncalves, T. Lourenco, M. Viana-Pereira, S. Costa, P. Linhares, R. Vaz, R. Nabico, J. Amorim, A. A. Pinto, R. M. Reis, and B. M. Costa “Effects of the Functional Hotair Rs920778 and Rs12826786 Genetic Variants in Glioma Susceptibility and Patient Prognosis”, J Neurooncol, 2017; 132(1): 27-34.

Ana Xavier-Magalhães*, Céline S. Gonçalves*, Tatiana Lourenço, Marta Pojo, Miguel Rocha, Maria Celeste Lopes, Inês Crespo, Olinda Rebelo, Herminio Tão, João Lima, Ricardo Moreira, Afonso A. Pinto, Chris Jones, Rui M. Reis, Joseph F. Costello, Nuno Sousa, Bruno M. Costa. “The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma”, Oncotarget, 2018; 9(21): 15740-15756.
*These authors contributed equally to this work.

Céline S. Gonçalves, Joana Vieira de Castro, Marta Pojo, Eduarda P. Martins, Sandro Queirós, Emmanuel Chautard, Ricardo Taipa, Manuel Melo Pires, Afonso A. Pinto, Fernando Pardal, Carlos Custódia, Cláudia C. Faria, Carlos Clara, Rui M. Reis, Nuno Sousa, Bruno M. Costa “WNT6 is a Novel Oncogenic Prognostic Biomarker in Human Glioblastoma”, Theranostics, 2018; 8(17): 4805-4823.

Selected Publications

Pojo M, Gonçalves CS, Xavier-Magalhães A, Oliveira AI, Gonçalves T, Correia S, Rodrigues AJ, Costa S, Pinto L, Pinto AA, Lopes JM, Reis RM, Rocha M, Sousa N, Costa BM. A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. Oncotarget, 6(10):7657-7674 (2015).

Copyright © 2012-2016 ICVS. All rights reserved.